Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-α

Journal of Viral Hepatitis

Volumn 16, Issue 7, 2009, Pages 506-512

  Toma, S ^a   Yamashiro, T ^b   Arakaki, S ^a   Shiroma, J ^a   Maeshiro, T ^a   Hibiya, K ^a   Sakamoto, N ^c   Kinjo, F ^b   Tateyama, M ^a   Fujita, J ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus; Human immunodeficiency virus; Nelfinavir

Indexed keywords

ALPHA2B INTERFERON; FIREFLY LUCIFERASE; NELFINAVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EXPRESSION VECTOR; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; REPORTER GENE; TREATMENT RESPONSE; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENES, REPORTER; HEPACIVIRUS; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON-ALPHA; LUCIFERASES; NELFINAVIR; VIRUS REPLICATION;

EID: 67650451290     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01102.x     Document Type: Article

References (34)

1. Hayashi PH, Flynn N, McCurdy SA, Kuramoto IK, Holland PV, Zeldis JB. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991 33 (3 177 180.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002 34 (6 831 837. (Pubitemid 34194855)
3. Salmon-Ceron D, Lewden C, Morlat P et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005 42 (6 799 805. (Pubitemid 40693195)
4. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis 2001 33 (10 1793 1795. (Pubitemid 33044553)
5. Valle Tovo C, Alves de Mattos A, Ribeiro de Souza A et al. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int 2007 27 (1 40 46. (Pubitemid 46150538)
6. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (Baltimore, MD) 1999 30 (4 1054 1058. (Pubitemid 29458296)
7. Puoti M, Bonacini M, Spinetti A et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001 183 (1 134 137. (Pubitemid 32043052)
8. Daar ES, Lynn H, Donfield S et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001 26 (5 466 472. (Pubitemid 32489026)
9. Goedert JJ, Hatzakis A, Sherman KE, Eyster ME. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. J Infect Dis 2001 184 (9 1202 1205. (Pubitemid 33010476)
10. Sherman KE, O'Brien J, Gutierrez AG et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993 31 (10 2679 2682. (Pubitemid 23284901)
11. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology (Baltimore, MD) 2004 39 (4 1147 1171. (Pubitemid 38428955)
12. Yokozaki S, Takamatsu J, Nakano I et al. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000 96 (13 4293 4299.
13. Ragni MV, Bontempo FA. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999 180 (6 2027 2029.
14. Babik JM, Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. J Virol 2003 77 (3 1940 1950. (Pubitemid 36110006)
15. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007 14 (6 371 386. (Pubitemid 46744053)
16. Trimoulet P, Neau D, Le Bail B et al. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol 2002 67 (2 143 151. (Pubitemid 34493428)
17. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002 186 (1 23 31. (Pubitemid 34666910)
18. Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995 333 (23 1528 1533.
19. den Brinker M, Wit FW, Wertheim-van Dillen PM et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (London, England) 2000 14 (18 2895 2902. (Pubitemid 32042753)
20. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS (London, England) 1998 12 (17 2289 2293. (Pubitemid 28526408)
21. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Filice G. Hepatotoxicity and nelfinavir: a meta-analysis. Clin Gastroenterol Hepatol 2005 3 (5 482 488. (Pubitemid 40616914)
22. Mitsuya H, Yarchoan R, Kageyama S, Broder S. Targeted therapy of human immunodeficiency virus-related disease. FASEB J 1991 5 (10 2369 2381. (Pubitemid 21905784)
23. Vlahakis SR, Bennett SA, Whitehead SN, Badley AD. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 2007 12 (5 969 977. (Pubitemid 46653299)
24. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002 109 (Suppl S81 S96.
25. Equils O, Shapiro A, Madak Z, Liu C, Lu D. Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation. Antimicrob Agents Chemother 2004 48 (10 3905 3911. (Pubitemid 39304620)
26. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001 75 (18 8516 8523. (Pubitemid 32768956)
27. Yokota T, Sakamoto N, Enomoto N et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 2003 4 (6 602 608. (Pubitemid 36939952)
28. Yamashiro T, Sakamoto N, Kurosaki M et al. Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3. J Gastroenterol 2006 41 (8 750 757. (Pubitemid 44446128)
29. Tanabe Y, Sakamoto N, Enomoto N et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 2004 189 (7 1129 1139. (Pubitemid 38457235)
30. Chung YM, Park KJ, Choi SY, Hwang SB, Lee SY. Hepatitis C virus core protein potentiates TNF-alpha-induced NF-kappaB activation through TRAF2-IKKbeta-dependent pathway. Biochem Biophys Res Commun 2001 284 (1 15 19. (Pubitemid 32924302)
31. Joo M, Hahn YS, Kwon M, Sadikot RT, Blackwell TS, Christman JW. Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta. J Virol 2005 79 (12 7648 7657. (Pubitemid 40756798)
32. Wagoner J, Austin M, Green J et al. Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J Virol 2007 81 (1 309 318. (Pubitemid 44975171)
33. Nakai K, Tanaka H, Hanada K et al. Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos Biol Fate Chem 2008 36 (9 1786 1793.
34. Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS (London, England). 1999 13 (7 870 871. (Pubitemid 29224598)